2021 remains a pivotal year for Treg directed therapies, with several trials due to read-out, and as we await the much-anticipated proof of concept, the opportunity in this space is exploding as we begin to see the potential of Treg therapies in autoimmune, transplant, and inflammation.
The 3rd Annual Treg Directed Therapies Summit returned online to unite senior-level execs from key large pharma, biotech, academia and service and solution providers to discuss how to target and translate Treg modifying therapies with enhanced persistence and durability safely and at scale.
Top 5 Reasons To Attend:
Explore the potential of chimeric antigen receptors with Tregs for the modulation of antigen specific responses with AZ Therapies, Quell Therapeutics and GentiBio
Examine clinical trial case studies with ILTOO Pharma and Stanford University to discuss how to translate effective and safe Treg directed therapies through the clinic
Learn different approaches to maximizing tolerance induction with antigen-specific Treg activation with Cour Pharmaceuticals and Amgen
Highlight the potential of using allogeneic cord blood derived T-regulatory cell therapy for treatment of COVID ARDS patients with John Hopkins University Hospital
Enhance Treg production and function using IL2-muteins and other small molecules with Pandion Therapeutics and University of Pennsylvania